JP7046081B2 - 治療薬の腸内送達のための製剤 - Google Patents

治療薬の腸内送達のための製剤 Download PDF

Info

Publication number
JP7046081B2
JP7046081B2 JP2019541672A JP2019541672A JP7046081B2 JP 7046081 B2 JP7046081 B2 JP 7046081B2 JP 2019541672 A JP2019541672 A JP 2019541672A JP 2019541672 A JP2019541672 A JP 2019541672A JP 7046081 B2 JP7046081 B2 JP 7046081B2
Authority
JP
Japan
Prior art keywords
therapeutic agent
nanoparticles
insulin
sensitive polymer
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534897A (ja
JP2019534897A5 (enExample
Inventor
ハベリ，インドゥー
ネリアッパン，カリアパナダール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curirx Inc
Original Assignee
Curirx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curirx Inc filed Critical Curirx Inc
Publication of JP2019534897A publication Critical patent/JP2019534897A/ja
Publication of JP2019534897A5 publication Critical patent/JP2019534897A5/ja
Application granted granted Critical
Publication of JP7046081B2 publication Critical patent/JP7046081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
JP2019541672A 2016-10-12 2017-10-12 治療薬の腸内送達のための製剤 Active JP7046081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/291,480 2016-10-12
US15/291,480 US11491114B2 (en) 2016-10-12 2016-10-12 Formulations for enteric delivery of therapeutic agents
PCT/US2017/056320 WO2018071655A1 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents

Publications (3)

Publication Number Publication Date
JP2019534897A JP2019534897A (ja) 2019-12-05
JP2019534897A5 JP2019534897A5 (enExample) 2020-11-19
JP7046081B2 true JP7046081B2 (ja) 2022-04-01

Family

ID=61830540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541672A Active JP7046081B2 (ja) 2016-10-12 2017-10-12 治療薬の腸内送達のための製剤

Country Status (8)

Country Link
US (2) US11491114B2 (enExample)
EP (1) EP3525772A4 (enExample)
JP (1) JP7046081B2 (enExample)
KR (2) KR102580705B1 (enExample)
CN (1) CN110049759A (enExample)
AU (2) AU2017341753B2 (enExample)
CA (1) CA3078570A1 (enExample)
WO (1) WO2018071655A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097251A1 (en) * 2017-11-17 2019-05-23 Intract Pharma Limited Novel compositions
KR20210145152A (ko) * 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
CN111743880B (zh) * 2020-06-05 2022-03-08 浙江大学医学院附属第一医院 一种单抗类药物口服纳米-微球制剂及其制备方法
US11365248B2 (en) 2020-06-29 2022-06-21 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating COVID-19 by inhalation

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517023A (ja) 2003-12-24 2007-06-28 サムヤン コーポレイション 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
JP2008163009A (ja) 2006-11-29 2008-07-17 Pfizer Prod Inc 腸溶ポリマーを含むナノ粒子とカゼインを含む医薬組成物
JP2009512631A (ja) 2005-09-15 2009-03-26 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ タンパク質／ペプチドの経口送達のためのｐＨ感受性ナノ粒子製剤
JP2010031003A (ja) 2008-07-01 2010-02-12 Nitto Denko Corp 表面被覆微粒子の医薬組成物
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US20100297237A1 (en) 2007-12-06 2010-11-25 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
JP2011519893A (ja) 2008-05-06 2011-07-14 グラクソ グループ リミテッド 生物活性薬の封入
JP2011529100A (ja) 2008-07-28 2011-12-01 フラメル テクノロジーズ ナノ粒子の調節放出に有用な微粒子状経口剤形
JP2012501305A (ja) 2008-09-01 2012-01-19 イオタ・ナノソリューションズ・リミテッド 医薬組成物に関連する改善
US20130034589A1 (en) 2011-08-04 2013-02-07 Nano And Advanced Materials Institute Limited pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY
JP2015503613A (ja) 2012-01-13 2015-02-02 エックススプレイ マイクロパーティクルズ アクチエボラグＸＳｐｒａｙ Ｍｉｃｒｏｐａｒｔｉｃｌｅｓ ＡＢ 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物
WO2016016665A1 (en) 2014-08-01 2016-02-04 Hovione International Ltd A method of preparing amorphous solid dispersion in submicron range by co-precipitation
US20160206741A1 (en) 2015-01-14 2016-07-21 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds
JP2017524726A (ja) 2014-05-30 2017-08-31 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 抗原結合性分子のナノ封入

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
CA2110899C (en) 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
JPH08507070A (ja) 1993-02-22 1996-07-30 アルザ・コーポレーション 活性物質の経口投与のための組成物
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
ES2280582T3 (es) 2001-09-19 2007-09-16 Elan Pharma International Limited Formulaciones de insulina en nanoparticulas.
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2005032511A2 (en) * 2003-09-30 2005-04-14 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
EA200600877A1 (ru) 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
US20040224019A1 (en) 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
CA2621577C (en) 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
WO2007036946A1 (en) * 2005-09-28 2007-04-05 Padma Venkitachalam Devarajan Compositions for enhanced absorption of biologically active agents
KR20090086060A (ko) 2006-09-12 2009-08-10 코스모 테크놀러지스 리미티드 단백질의 경구 또는 직장 투여를 위한 약학적 조성물
AU2007333528B2 (en) 2006-10-05 2013-10-17 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
US20100021549A1 (en) 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
US20140120162A1 (en) 2011-06-06 2014-05-01 Perosphere Inc. Bioadhesive Drug Delivery Compositions
EP2548571A1 (en) * 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
CN102908332B (zh) * 2011-08-04 2014-04-16 纳米及先进材料研发院有限公司 用于口服胰岛素递送的包含阳离子纳米粒子的肠溶包衣胶囊
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
KR20190077124A (ko) 2011-10-21 2019-07-02 스템제닉스 인코포레이티드 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
US9833522B2 (en) * 2013-12-23 2017-12-05 The Research Foundation For The State University Of New York Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use
US9370488B2 (en) 2014-07-21 2016-06-21 Kimia Zist Parsian Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin
CN104739806B (zh) * 2015-04-17 2018-04-03 黑龙江大学 口服胰岛素复合微囊及制备方法
CN105056212B (zh) * 2015-07-14 2018-06-15 江西省药物研究所 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517023A (ja) 2003-12-24 2007-06-28 サムヤン コーポレイション 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
JP2009512631A (ja) 2005-09-15 2009-03-26 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ タンパク質／ペプチドの経口送達のためのｐＨ感受性ナノ粒子製剤
JP2008163009A (ja) 2006-11-29 2008-07-17 Pfizer Prod Inc 腸溶ポリマーを含むナノ粒子とカゼインを含む医薬組成物
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US20100297237A1 (en) 2007-12-06 2010-11-25 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
JP2011519893A (ja) 2008-05-06 2011-07-14 グラクソ グループ リミテッド 生物活性薬の封入
JP2010031003A (ja) 2008-07-01 2010-02-12 Nitto Denko Corp 表面被覆微粒子の医薬組成物
JP2011529100A (ja) 2008-07-28 2011-12-01 フラメル テクノロジーズ ナノ粒子の調節放出に有用な微粒子状経口剤形
JP2012501305A (ja) 2008-09-01 2012-01-19 イオタ・ナノソリューションズ・リミテッド 医薬組成物に関連する改善
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US20130034589A1 (en) 2011-08-04 2013-02-07 Nano And Advanced Materials Institute Limited pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY
JP2015503613A (ja) 2012-01-13 2015-02-02 エックススプレイ マイクロパーティクルズ アクチエボラグＸＳｐｒａｙ Ｍｉｃｒｏｐａｒｔｉｃｌｅｓ ＡＢ 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物
JP2017524726A (ja) 2014-05-30 2017-08-31 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 抗原結合性分子のナノ封入
WO2016016665A1 (en) 2014-08-01 2016-02-04 Hovione International Ltd A method of preparing amorphous solid dispersion in submicron range by co-precipitation
JP2017523205A (ja) 2014-08-01 2017-08-17 ホビオネ インターナショナル エルティーディー 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
US20160206741A1 (en) 2015-01-14 2016-07-21 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Nanomedicine，2011年，6，2429-2435

Also Published As

Publication number Publication date
AU2024201438A1 (en) 2024-03-21
AU2017341753A1 (en) 2019-05-30
CN110049759A (zh) 2019-07-23
US11491114B2 (en) 2022-11-08
JP2019534897A (ja) 2019-12-05
BR112019007539A2 (pt) 2019-07-02
KR20190086446A (ko) 2019-07-22
EP3525772A4 (en) 2020-06-03
US20230034964A1 (en) 2023-02-02
US20180098946A1 (en) 2018-04-12
WO2018071655A1 (en) 2018-04-19
EP3525772A1 (en) 2019-08-21
CA3078570A1 (en) 2018-04-19
KR20230135694A (ko) 2023-09-25
KR102580705B1 (ko) 2023-09-19
AU2017341753B2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
US20230034964A1 (en) Formulations for Enteric Delivery of Therapeutic Agents
RU2663687C2 (ru) Композиции наночастиц альбумина и паклитаксела
ES2700278T3 (es) Formulaciones para efectores de la unión estrecha
Moritz et al. Recent developments in the application of polymeric nanoparticles as drug carriers
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
US20020054914A1 (en) Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
JP6533232B2 (ja) 親水性活性化合物のナノカプセル化
CN102387789A (zh) 含有无定形cddo-me的延迟释放口服组合物
JP2013525351A (ja) ナノ粒子の医薬組成物
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
E Leucuta Drug delivery systems with modified release for systemic and biophase bioavailability
JP2020524715A (ja) 癌および眼疾患の治療のためのアルブミンナノ粒子
JP2013519649A (ja) 上皮増殖因子の経口投与可能薬学的ペレット
Das et al. Chitosan-based systems for oral drug delivery applications
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
BR112019007539B1 (pt) Formulação oral de um agente terapêutico, método de preparação de uma formulação administrável por via oral de um agente terapêutico e uso da referida formulação oral
Iswandana et al. Delivery of Potential Drugs to The Colon: Challenges and Strategies.
M. Lopes et al. Novel delivery systems for anti-allergic agents: allergic disease and innovative treatments
JP2010514679A (ja) 制御放出組成物及び方法
Mohammed Development of Once-Daily Mycophenolate Mofetil Sustained Release Oral Nanoparticles
Lu et al. Appendix F—Chapter II. 5.16—Drug Delivery Systems: H, Mucosal Drug Delivery
CN116942634A (zh) 一种速溶型纳米粒子组合物及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7046081

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250